Literature DB >> 1596688

Pharmacological characterization of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist.

A Doble1, D Girdlestone, O Piot, D Allam, J Betschart, A Boireau, A Dupuy, C Guérémy, J Ménager, J L Zundel.   

Abstract

1. RP 62203 (2-[3-(4-(4-fluorophenyl)-piperazinyl)propyl]naphto[1,8- ca]isothiazole-1,1-dioxide) is a novel naphtosultam derivative which shows very high affinity for 5-HT2 receptors in the rat cerebral cortex (Ki = 50.0 pM). 2. RP 62203 is relatively selective for this sub-type of 5-hydroxytryptamine (5-HT) receptor, having lower affinity for the 5-HT1A receptor and very low affinity for the 5-HT, receptor. RP 62203 displayed low to moderate affinity for alpha 1-adrenoceptors, dopamine D2 receptors and histamine H1 receptors. 3. In vivo binding experiments demonstrated that oral administration of low doses of RP 62203 led to a long-lasting (greater than 6 h) occupation of cortical 5-HT2 receptors (ID50 = 0.39 mgkg-1). 4. In cortical slices from the neonatal rat, RP 62203 potently inhibited inositol phosphate formation evoked by 5-HT, with an IC50 of 7.76 nM. 5. The activity of neurones in the raphé and their responses to microiontophoretically applied 5-HT were studied with extracellular recording electrodes in the anaesthetized rat. RP 62203 potently and dose-dependently blocked excitations evoked by 5-HT when administered at doses of 0.5-4.0 mg kg-1, i.p. In contrast, neither 5-HT-evoked depressions nor glutamate-evoked excitations of raphé neuronal firing were blocked by RP 62203 at doses as high as 8.0 mg kg-1, i.p. 6. Head twitches induced by 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) could be abolished by low doses of RP 62203 in mice (ED50 = 0.44 mg kg-1, p.o.) and in rats (ED50 = 1.54 p.o.). Similar results were obtained with mescaline and 5-hydroxytryptophan (5-HTP). 7. The potency of RP 62203 was compared with that of three other 5-HT2 receptor antagonists, ritanserin, ICI 169,369 and ICI 170,809. In all models, RP 62203 showed similar activity to ritanserin, whilst either ICI 169,369 or ICI 170,809 was several fold less active. 8. It is concluded that RP 62203 is a potent and selective antagonist at 5-HT2 receptors in the rodent central nervous system.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1596688      PMCID: PMC1908636          DOI: 10.1111/j.1476-5381.1992.tb14206.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  59 in total

1.  Beta adrenergic receptor binding in membrane preparations from mammalian brain.

Authors:  D B Bylund; S H Snyder
Journal:  Mol Pharmacol       Date:  1976-07       Impact factor: 4.436

2.  Characterization of the 5-HT1B recognition site in rat brain: binding studies with (-)[125I]iodocyanopindolol.

Authors:  D Hoyer; G Engel; H O Kalkman
Journal:  Eur J Pharmacol       Date:  1985-11-26       Impact factor: 4.432

3.  [3H]Batrachotoxinin A 20-alpha-benzoate binding to sodium channels in rat brain: characterization and pharmacological significance.

Authors:  P J Pauwels; J E Leysen; P M Laduron
Journal:  Eur J Pharmacol       Date:  1986-05-27       Impact factor: 4.432

4.  Electrophysiological evidence that spiperone is an antagonist of 5-HT1A receptors in the dorsal raphe nucleus.

Authors:  J T Lum; M F Piercey
Journal:  Eur J Pharmacol       Date:  1988-04-27       Impact factor: 4.432

5.  Pharmacological characterization of serotonin-stimulated phosphoinositide turnover in brain regions of the immature rat.

Authors:  Y Claustre; L Rouquier; B Scatton
Journal:  J Pharmacol Exp Ther       Date:  1988-03       Impact factor: 4.030

6.  Two types of somatostatin receptors differentiated by cyclic somatostatin analogs.

Authors:  V T Tran; M F Beal; J B Martin
Journal:  Science       Date:  1985-04-26       Impact factor: 47.728

7.  Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine.

Authors:  P B Bradley; G Engel; W Feniuk; J R Fozard; P P Humphrey; D N Middlemiss; E J Mylecharane; B P Richardson; P R Saxena
Journal:  Neuropharmacology       Date:  1986-06       Impact factor: 5.250

8.  Two bradykinin binding sites with picomolar affinities.

Authors:  D C Manning; R Vavrek; J M Stewart; S H Snyder
Journal:  J Pharmacol Exp Ther       Date:  1986-05       Impact factor: 4.030

9.  Evidence for a displaceable non-specific [3H]neurotensin binding site in rat brain.

Authors:  A Schotte; J E Leysen; P M Laduron
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-08       Impact factor: 3.000

10.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

Authors:  J E Leysen; W Gommeren; P Van Gompel; J Wynants; P F Janssen; P M Laduron
Journal:  Mol Pharmacol       Date:  1985-06       Impact factor: 4.436

View more
  2 in total

1.  Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations.

Authors:  B Costall; R J Naylor
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 2.  5-HT radioligands for human brain imaging with PET and SPECT.

Authors:  Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen
Journal:  Med Res Rev       Date:  2011-06-14       Impact factor: 12.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.